HOUSE_OVERSIGHT_024042.jpg
2.6 MB
Extraction Summary
1
People
3
Organizations
3
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Investment strategy document / private placement memorandum
File Size:
2.6 MB
Summary
This document is page 31 of a confidential investment strategy memorandum for New Leaf Venture Partners' third fund (NLV-III). It outlines the fund's strategy to invest in 24-28 companies, primarily in the U.S., with a 50-60% allocation focus on Biopharmaceuticals, alongside Information Convergence and Medical Devices. The document bears a House Oversight Bates stamp, indicating it was obtained as part of a congressional investigation, likely regarding financial connections.
People (1)
| Name | Role | Context |
|---|---|---|
| Fund Managers | Investment Managers |
Generic reference to the managers of New Leaf Venture Partners who will serve on boards and manage the portfolio.
|
Organizations (3)
| Name | Type | Context |
|---|---|---|
| New Leaf Venture Partners |
The venture capital firm issuing the strategy document.
|
|
| NLV-III |
New Leaf Venture Partners Fund III; the specific investment vehicle described.
|
|
| House Oversight Committee |
Implied by the Bates stamp 'HOUSE_OVERSIGHT_024042'.
|
Locations (3)
| Location | Context |
|---|---|
|
Primary domicile for the estimated 24-28 portfolio companies.
|
|
|
Secondary potential location for portfolio companies.
|
|
|
Secondary potential location for portfolio companies.
|
Relationships (1)
The Fund Managers intend to serve on the boards of directors for the majority of the companies in the portfolio...
Key Quotes (3)
"NLV-III will be invested in a diversified portfolio across four sectors: a primary focus on Biopharmaceuticals and Information Convergence, and a secondary focus on Medical Devices and Biological Research Tools & Infrastructure."Source
HOUSE_OVERSIGHT_024042.jpg
Quote #1
"The Fund Managers will invest the Fund in a diversified portfolio composed of an estimated 24 - 28 companies that will be predominantly domiciled in the U.S."Source
HOUSE_OVERSIGHT_024042.jpg
Quote #2
"biopharmaceutical investments will be the core focus for NLV-III and will comprise approximately 50% - 60% of the Fund."Source
HOUSE_OVERSIGHT_024042.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document